FOXM1 is a therapeutic target for high-risk multiple myeloma

Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma

(2015) Y. Yang et al.   CANCER RESEARCH

FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells

(2015) Ai-hua Gong et al.   CANCER RESEARCH

Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features

(2015) Dragana Kopanja et al.   JOURNAL OF HEPATOLOGY

Adoptive B-cell transfer mouse model of human myeloma

(2015) V S Tompkins et al.   LEUKEMIA

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

(2015) Ruben Niesvizky et al.   LEUKEMIA & LYMPHOMA

The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells

(2015) Yu Hou et al.   NATURE IMMUNOLOGY

OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance

(2015) U Karunarathna et al.   ONCOGENE

Expanding the scope of fused pyrimidines as kinase inhibitor scaffolds: synthesis and modification of pyrido[3,4-d]pyrimidines

(2015) Paolo Innocenti et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients

(2015) Elad Ziv et al.   Nature Communications

FOXM1 binds directly to non-consensus sequences in the human genome

(2015) Deborah A. Sanders et al.   GENOME BIOLOGY

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

(2015)   Oncotarget

FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells

(2015) Wen-Tai Chiu et al.   Oncotarget

FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance

(2014) Stefania Zona et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

(2014) Ruth Scheicher et al.   BLOOD

Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance

(2014) Mihaela Marina   Frontiers in Bioscience-Landmark

GP130 activation induces myeloma and collaborates with MYC

(2014) Tobias Dechow et al.   JOURNAL OF CLINICAL INVESTIGATION

PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model

(2014) T Motiwala et al.   LEUKEMIA

A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue

(2014) Ping Wu et al.   LEUKEMIA & LYMPHOMA

Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism

(2014) C-M Hu et al.   ONCOGENE

Forkhead Box M1 Regulates Quiescence-Associated Radioresistance of Human Head and Neck Squamous Carcinoma Cells

(2014) Jaimee C. Eckers et al.   RADIATION RESEARCH

Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition

(2014) Michael V. Gormally et al.   Nature Communications

RAR 2 expression confers myeloma stem cell features

(2013) Y. Yang et al.   BLOOD

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells

(2013) T. Tanno et al.   BLOOD

Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma

(2013) Roman Hajek et al.   BRITISH JOURNAL OF HAEMATOLOGY

NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

(2013) Wen Zhou et al.   CANCER CELL

Dysregulated Expression of FOXM1 Isoforms Drives Progression of Pancreatic Cancer

(2013) Xiangyu Kong et al.   CANCER RESEARCH

Genomic instability in multiple myeloma: mechanisms and therapeutic implications

(2013) Paola Neri et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Foxm1 Expression in Prostate Epithelial Cells Is Essential for Prostate Carcinogenesis

(2013) Yuqi Cai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma

(2013) Z. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling

(2013) Van S. Tompkins et al.   PLoS One

18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib

(2013) K Duncan et al.   Blood Cancer Journal

A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice

(2013) Y Hu et al.   Blood Cancer Journal

Targeting FOXM1 in cancer

(2012) Marianna Halasi et al.   BIOCHEMICAL PHARMACOLOGY

Clinical and prognostic role of annexin A2 in multiple myeloma

(2012) A. Seckinger et al.   BLOOD

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

FoxM1 and Wnt/ -Catenin Signaling in Glioma Stem Cells

(2012) A. Gong et al.   CANCER RESEARCH

Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma

(2012) S. Uddin et al.   HAEMATOLOGICA

A gene expression signature for high-risk multiple myeloma

(2012) R Kuiper et al.   LEUKEMIA

FOXM1 Induces a Global Methylation Signature That Mimics the Cancer Epigenome in Head and Neck Squamous Cell Carcinoma

(2012) Muy-Teck Teh et al.   PLoS One

Detection of IGF2BP3, HOXB7, and NEK2 mRNA Expression in Brush Cytology Specimens as a New Diagnostic Tool in Patients with Biliary Strictures

(2012) Hans Dieter Nischalke et al.   PLoS One

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management

(2011) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

FOXM1: From cancer initiation to progression and treatment

(2011) Chuay-Yeng Koo et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

(2011) Lars Anders et al.   CANCER CELL

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

(2011) E. C. Lee et al.   CLINICAL CANCER RESEARCH

The transcription factor FOXM1 is a cellular target of the natural product thiostrepton

(2011) Nagaratna S. Hegde et al.   Nature Chemistry

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

(2010) F. van Rhee et al.   BLOOD

CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma

(2010) H. Chang et al.   HAEMATOLOGICA

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC

(2009) D F Calvisi et al.   GUT

FoxM1 Is a General Target for Proteasome Inhibitors

(2009) Uppoor G. Bhat et al.   PLoS One

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH